The Food and Drug Administration has granted Fast Track designation to emrusolmin (TEV-56286) for the treatment of multiple system atrophy.

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for ...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotech company focused on next-generation immunomodulation ...

Research Triangle Park, North Carolina Friday, September 19, 2025, 10:00 Hrs [IST] ...

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Teva Pharmaceutical Industries ...

MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ongoing ...

"Multiple System Atrophy Clinical Trials Analysis"DelveInsight's,“Multiple System Atrophy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene ...